Skip to content

Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients

Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04804566
Enrollment
44
Registered
2021-03-18
Start date
2023-03-01
Completion date
2023-11-01
Last updated
2024-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry Disease

Keywords

Hypohidrosis, Proteinuria, Angiokeratoma

Brief summary

The objective of this study is to increase the understanding surrounding the choices presented to patients and families impacted by Fabry disease.

Detailed description

This will be a cross-sectional study conducted in approximately 130 individuals (or representative parents/caregivers of patients) living with Fabry disease. All study participants will complete the RSVP followed by a structured interview conducted by trained interviewers. It is estimated that each respondent will need up to 60 minutes for the entire process; 10 minutes to complete the RSVP including uploading the proof of Fabry disease diagnosis or verifying membership with Fabry groups, including but not limited to: Fabry Support and Information Group, National Fabry Disease Foundation, MPS Society UK, Morbus Fabry Selbsthilfergruppe, Fabry International Network, or others, and approximately 50 minutes to complete the interview.

Interventions

This is a non-interventional study

Sponsors

Engage Health Inc.
CollaboratorINDUSTRY
Amicus Therapeutics
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participant must be a person with Fabry disease who is 18 years or older or the parent/legal guardian of a living person with Fabry disease who is under the age of 18 years or who are 18 years and older who are unable to answer for themselves. * Confirmed diagnosis of Fabry disease with written proof of disease provided * Must have a genetic mutation that is amenable to oral therapy * Resident of Germany, the U.K or the U.S. * Able to read, write and communicate in German, or English. * Able to grant informed consent * Willing to participate in a 50 to 60-minute telephone interview, including follow up questions (if necessary) and information regarding adverse events (if necessary).

Exclusion criteria

* Inability to meet any of the inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
Patterns and Trends that Provide Evidence and Context for the Treatment Choices and Experiences of Those with Fabry Disease1-2 monthsThe goal of the statistical analysis is to uncover patterns and trends that provide both evidence and context for the treatment choices and experiences of patients and families impacted by Fabry disease. All findings will be summarized in the final report, which will not identify any respondent as described above. At the conclusion of this study, the researchers may publish their findings in a medical / scientific journal.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026